10-Q: Chemed Corp Reports Strong Q1 2025 Results, Driven by Hospice and Plumbing Services

Chemed Corporation's Q1 2025 shows revenue and earnings growth, fueled by VITAS Healthcare and Roto-Rooter.

Summary

• Chemed Corporation reported its Q1 2025 financial results, showing an increase in service revenues and sales by 9.8% to $646.94 million compared to $589.23 million in Q1 2024.
• Net income increased to $71.757 million, or $4.91 per share, compared to $65.017 million, or $4.30 per share, in the prior year.
• The VITAS segment saw a 15.1% increase in revenue, driven by an 11.9% increase in days-of-care and a 3.2% increase in Medicare reimbursement rates.
• Roto-Rooter's revenue increased by 1.8%, with growth in excavation and water restoration offsetting declines in plumbing and drain cleaning.
• Adjusted EBITDA increased to $121.692 million from $114.622 million in the prior year.
• The company repurchased 50,000 shares of its capital stock at an average price of $595.15 per share.
• Chemed is in compliance with all debt covenants as of March 31, 2025, and has $404.5 million of unused lines of credit available.

Sentiment

Score: 8

Explanation: The report presents a positive outlook with strong financial results and growth in key segments. While there are some challenges and risks, the overall tone is optimistic and indicates a healthy business performance.

Positives

• Overall revenue and net income increased year-over-year.
• VITAS segment shows strong growth in revenue and days of care.
• Roto-Rooter's excavation and water restoration services are performing well.
• The company is in compliance with all debt covenants.
• Chemed has a significant amount of unused credit available.
• The Covenant Care acquisition contributed approximately $11.5 million to $12.5 million in revenue and $1.8 million to $2.0 million in net income.

Negatives

• Roto-Rooter experienced a decrease in plumbing and drain cleaning revenues.
• VITAS' gross margin remained flat year-over-year.
• Roto-Rooter's gross margin decreased from 51.9% to 50.9%.
• Net cash provided by operating activities decreased $51.8 million from March 31, 2024 to March 31, 2025.

Risks

• Macroeconomic trends such as inflation and tariffs could negatively affect net sales and profitability.
• The VITAS segment operates in a heavily regulated industry, which subjects the company to inquiries and investigations.
• A disruption from VITAS' main service providers for pharmacy services and medical supplies could adversely impact operations.
• Significant tariffs on certain products, such as steel for Roto-Rooter's cabling machines and pharmaceuticals utilized by VITAS, could materially increase costs.

Future Outlook

Management anticipates that operating income and cash flows will be sufficient to operate the business and meet commitments for the foreseeable future.

Management Comments

• Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.
• Management believes its liquidity and sources of capital are satisfactory for the Company's needs in the foreseeable future.

Industry Context

Chemed operates in the healthcare (hospice) and home services (plumbing and drain cleaning) industries. The growth in the VITAS segment reflects the increasing demand for hospice care services, driven by an aging population. Roto-Rooter's performance is influenced by housing market conditions and consumer spending on home maintenance and repair.

Comparison to Industry Standards

• While specific competitor data isn't provided, Chemed's growth in hospice care aligns with the broader trend of increased demand for these services.
• Competitors in the hospice space include LHC Group and Amedisys, while Roto-Rooter competes with other national and regional plumbing and drain cleaning service providers.
• Chemed's adjusted EBITDA margin of 18.8% is a key metric to compare against industry peers to assess operational efficiency.

Legal Proceedings

• VITAS is one of a group of hospice providers selected by the Office of the Inspector Generals (OIG) Office of Audit Services (OAS) for inclusion in an audit of the provision of elevated level-of-care hospice services.
• On February 3, 2025, an Administrative Law Judge (ALJ) ruled that VITAS care met Medicares hospice standards for the applicable higher level of care as originally billed for all but one of the claims appealed, and therefore VITAS was entitled to receive payment for all such claims.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue, earnings, and share repurchases.
• Employees: Potential for continued employment and compensation.
• Customers/Patients: Continued access to hospice and plumbing services.
• Suppliers: Ongoing business relationships.

Next Steps

• The company will continue to monitor macroeconomic trends and uncertainties.
• Management will continue to evaluate cash utilization alternatives.
• The company is finalizing the impacts of ASU 2023-09 and expects to incorporate within our footnote disclosures in our Annual Report on Form 10-K.
• The Company is currently analyzing the impact of the ASU 2024-03 on the current footnote disclosures.

Key Dates

Keywords

Chemed, VITAS, Roto-Rooter, hospice, plumbing, financial results, Q1 2025, revenue, EBITDA, earnings per share